PentaBind utilizes a proprietary platform combining AI, molecular modeling, and wet-lab methods to design multi-attribute, drug-like aptamers. This technology produces small, highly selective binding molecules with tunable stability and predictable sequences for therapeutic and diagnostic applications. The company focuses on overcoming traditional aptamer design limitations to enable advanced drug development, including efficient penetration of tumor microenvironments.
Funding
$845K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional aptamer design for therapeutic development relies on labor-intensive wet-laboratory methods, which are time-consuming, have limited search capabilities, and often yield aptamers with suboptimal drug-like qualities. This results in slow development cycles and reduced success rates in identifying effective aptamer-based therapeutics.
Solution
PentaBind utilizes generative AI to accelerate and improve aptamer design, overcoming the limitations of conventional wet-laboratory approaches. Their AI platform designs aptamers that selectively bind to target molecules, including cancer protein variants, without requiring complex drug conjugate linkers. The AI models balance multiple design features, such as binding affinity, specificity, and stability, to generate aptamers with enhanced drug-like properties. PentaBind's technology significantly reduces experimental time and increases the success rate of aptamer design by searching a much larger chemical space than traditional methods.
Target Audience
The primary target audience includes pharmaceutical companies, biotech firms, and research institutions involved in therapeutic development, particularly those focused on oncology and other diseases with unmet needs.
Features
- Generative AI platform for de novo aptamer design with enhanced binding affinity and specificity
- AI models trained on a proprietary, large-scale dataset of aptamer-target interactions generated in-house
- Ability to discriminate between closely related protein variants, such as those found in cancer
- Designed aptamers are smaller in size, facilitating improved tumor penetration
- Aptamers are designed to be non-immunogenic, reducing the risk of adverse immune reactions